Medical devices, healthcare technology and the business of care
PMA approval · P230001

ColoSense

Geneoscopy, Inc. · Decision date May 3, 2024

MEDTECHLEDGER EXPLANATIONP230001

What did the FDA approve?

The FDA decision dated 2024-05-03 for P230001 marks original premarket approval of ColoSense, an in vitro diagnostic test detecting colorectal neoplasia associated RNA markers and occult hemoglobin in human stool. The indication covers adults 45 years or older at average risk for colorectal cancer. The supplied record lists no supplement type, so no modification to an earlier clearance is established; the identifier alone does not connect this to a prior PMA.

Per the source statement, a positive result may indicate colorectal cancer, advanced adenomas, or serrated precancerous lesions and should be followed by colonoscopy. The statement also says ColoSense is not a replacement for diagnostic or surveillance colonoscopy in high-risk individuals. These are the applicant's stated intended uses; the record does not supply independent evidence of safety or clinical effectiveness, and it does not describe trial data, performance figures, or the composition of the RNA marker panel.

FDA approval order statement

ColoSense is a qualitative in vitro diagnostic test intended for the detection of colorectal neoplasia associated RNA markers and for the presence of occult hemoglobin in human stool. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA) or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
May 3, 2024

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230001
Regulatory pathway
Premarket approval application
Product code
SBB
Decision code
APPR
Decision date
May 3, 2024
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, Colorectal Neoplasia, RNA Markers and Hemoglobin detection.

Product code
SBB
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P230001 received

    Application receipt date recorded by FDA.

  2. P230001 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P230001. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230001

Product / regulatory recordCompanyPathwayDecision dateSource
ColoSenseP230001/S010
Geneoscopy, Inc.PMA supplementAug 14, 2025FDA
ColoSenseP230001/S009
Geneoscopy, Inc.PMA supplementSep 15, 2025FDA
ColoSenseP230001/S011
Geneoscopy, Inc.PMA supplementOct 24, 2025FDA
ColoSenseP230001/S012
Geneoscopy, Inc.PMA supplementAug 27, 2026FDA
ColoSenseP230001/S014
Geneoscopy, Inc.PMA supplementSep 8, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Geneoscopy, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2220 Welsch Industrial Ct., St. Louis, MO, 63146

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records